| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:18048496 | IVR | 0.25 % | 0.25 % | Increased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 0.25 % | 0.25 % | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| PMID:24740835 | IVTH | 0.000000001 - 0.000001 M | 0.000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:24803507 | IVR | 0.5 % | 0.5 % | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 % | 0.5 % | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 % | 0.2 % | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| PMID:25826746 | IVTH | 0.0000005 - 0.000005 M | 0.0000005 - 0.000005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:29376079 | IVTH | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:31869449 | IVR | 3 mg/kg | 3 mg/kg | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 3 mg/kg | 3 mg/kg | Affects implantation in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Decreased progesterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | - | No significant effects observed | - | |
| IVR | 1.5 mg/kg | - | No significant effects observed | - |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.